Leniolisib

• Description :

  Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.

• Product Name Alternative :

  CDZ173

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  PI3K

• Type :

  Reference compound

• Related Pathways :

  PI3K/Akt/mTOR

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/Leniolisib.html

• Purity :

  99.38

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  CCC(N1C[C@@H](NC2=C(CN(C3=CC(C(F)(F)F)=C(OC)N=C3)CC4)C4=NC=N2)CC1)=O

• Molecular Formula :

  C21H25F3N6O2

• Molecular Weight :

  450.46

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406|[2]Hoegenauer K, et al. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med Chem Lett. 2017 Aug 25;8 (9) :975-980.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ

• CAS Number :

  [1354690-24-6]